0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Psychiatric and Nervous Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-17G11737
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Psychiatric and Nervous Drugs Market Research Report 2022
BUY CHAPTERS

Global Psychiatric and Nervous Drugs Market Research Report 2025

Code: QYRE-Auto-17G11737
Report
January 2025
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Psychiatric and Nervous Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Psychiatric and Nervous Drugs Market

Psychiatric and Nervous Drugs Market

The global market for Psychiatric and Nervous Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
A psychiatric and nervous drug (psychiatric or psychotropic medication) is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system.
Mental health and well-being affect our daily lives. Psychotropic medications can be an important part of the tools available to help keep us well.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Psychiatric and Nervous Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychiatric and Nervous Drugs.
The Psychiatric and Nervous Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Psychiatric and Nervous Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psychiatric and Nervous Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Psychiatric and Nervous Drugs Market Report

Report Metric Details
Report Name Psychiatric and Nervous Drugs Market
CAGR 5%
Segment by Type
  • Antidepressants
  • Anti-anxiety
  • Antipsychotic
  • Mood Stabilizing
  • Stimulant Medications
  • Others
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical, Takeda, NHU Group, Shionogi, APOTEX, Chengdu Kanghong Pharmaceutical, HUAHAI, Zhejiang Jianfeng, Beijing Winsunny Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Psychiatric and Nervous Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Psychiatric and Nervous Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Psychiatric and Nervous Drugs Market report?

Ans: The main players in the Psychiatric and Nervous Drugs Market are Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical, Takeda, NHU Group, Shionogi, APOTEX, Chengdu Kanghong Pharmaceutical, HUAHAI, Zhejiang Jianfeng, Beijing Winsunny Pharmaceutical

What are the Application segmentation covered in the Psychiatric and Nervous Drugs Market report?

Ans: The Applications covered in the Psychiatric and Nervous Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Psychiatric and Nervous Drugs Market report?

Ans: The Types covered in the Psychiatric and Nervous Drugs Market report are Antidepressants, Anti-anxiety, Antipsychotic, Mood Stabilizing, Stimulant Medications, Others

1 Psychiatric and Nervous Drugs Market Overview
1.1 Product Definition
1.2 Psychiatric and Nervous Drugs by Type
1.2.1 Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Psychiatric and Nervous Drugs by Application
1.3.1 Global Psychiatric and Nervous Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
1.4.1 Global Psychiatric and Nervous Drugs Revenue 2020-2031
1.4.2 Global Psychiatric and Nervous Drugs Sales 2020-2031
1.4.3 Global Psychiatric and Nervous Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Psychiatric and Nervous Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
2.7 Global Key Manufacturers of Psychiatric and Nervous Drugs, Date of Enter into This Industry
2.8 Global Psychiatric and Nervous Drugs Market Competitive Situation and Trends
2.8.1 Global Psychiatric and Nervous Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
2.8.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Psychiatric and Nervous Drugs Market Scenario by Region
3.1 Global Psychiatric and Nervous Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Psychiatric and Nervous Drugs Sales by Region: 2020-2031
3.2.1 Global Psychiatric and Nervous Drugs Sales by Region: 2020-2025
3.2.2 Global Psychiatric and Nervous Drugs Sales by Region: 2026-2031
3.3 Global Psychiatric and Nervous Drugs Revenue by Region: 2020-2031
3.3.1 Global Psychiatric and Nervous Drugs Revenue by Region: 2020-2025
3.3.2 Global Psychiatric and Nervous Drugs Revenue by Region: 2026-2031
3.4 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.4.1 North America Psychiatric and Nervous Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Psychiatric and Nervous Drugs Sales by Country (2020-2031)
3.4.3 North America Psychiatric and Nervous Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.5.1 Europe Psychiatric and Nervous Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Psychiatric and Nervous Drugs Sales by Country (2020-2031)
3.5.3 Europe Psychiatric and Nervous Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Psychiatric and Nervous Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.7.1 Latin America Psychiatric and Nervous Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Psychiatric and Nervous Drugs Sales by Country (2020-2031)
3.7.3 Latin America Psychiatric and Nervous Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric and Nervous Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric and Nervous Drugs Sales by Type (2020-2031)
4.1.1 Global Psychiatric and Nervous Drugs Sales by Type (2020-2025)
4.1.2 Global Psychiatric and Nervous Drugs Sales by Type (2026-2031)
4.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2020-2031)
4.2 Global Psychiatric and Nervous Drugs Revenue by Type (2020-2031)
4.2.1 Global Psychiatric and Nervous Drugs Revenue by Type (2020-2025)
4.2.2 Global Psychiatric and Nervous Drugs Revenue by Type (2026-2031)
4.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Psychiatric and Nervous Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Psychiatric and Nervous Drugs Sales by Application (2020-2031)
5.1.1 Global Psychiatric and Nervous Drugs Sales by Application (2020-2025)
5.1.2 Global Psychiatric and Nervous Drugs Sales by Application (2026-2031)
5.1.3 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2020-2031)
5.2 Global Psychiatric and Nervous Drugs Revenue by Application (2020-2031)
5.2.1 Global Psychiatric and Nervous Drugs Revenue by Application (2020-2025)
5.2.2 Global Psychiatric and Nervous Drugs Revenue by Application (2026-2031)
5.2.3 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Psychiatric and Nervous Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Company Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Company Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Company Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Company Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Company Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.7.1 Astrazeneca Company Information
6.7.2 Astrazeneca Description and Business Overview
6.7.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Company Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Company Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Company Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Company Information
6.11.2 Otsuka Pharmaceutical Description and Business Overview
6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Company Information
6.13.2 NHU Group Description and Business Overview
6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Company Information
6.14.2 Shionogi Description and Business Overview
6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Company Information
6.15.2 APOTEX Description and Business Overview
6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 Chengdu Kanghong Pharmaceutical
6.16.1 Chengdu Kanghong Pharmaceutical Company Information
6.16.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
6.17 HUAHAI
6.17.1 HUAHAI Company Information
6.17.2 HUAHAI Description and Business Overview
6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
6.17.5 HUAHAI Recent Developments/Updates
6.18 Zhejiang Jianfeng
6.18.1 Zhejiang Jianfeng Company Information
6.18.2 Zhejiang Jianfeng Description and Business Overview
6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
6.18.5 Zhejiang Jianfeng Recent Developments/Updates
6.19 Beijing Winsunny Pharmaceutical
6.19.1 Beijing Winsunny Pharmaceutical Company Information
6.19.2 Beijing Winsunny Pharmaceutical Description and Business Overview
6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric and Nervous Drugs Industry Chain Analysis
7.2 Psychiatric and Nervous Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric and Nervous Drugs Production Mode & Process Analysis
7.4 Psychiatric and Nervous Drugs Sales and Marketing
7.4.1 Psychiatric and Nervous Drugs Sales Channels
7.4.2 Psychiatric and Nervous Drugs Distributors
7.5 Psychiatric and Nervous Drugs Customer Analysis
8 Psychiatric and Nervous Drugs Market Dynamics
8.1 Psychiatric and Nervous Drugs Industry Trends
8.2 Psychiatric and Nervous Drugs Market Drivers
8.3 Psychiatric and Nervous Drugs Market Challenges
8.4 Psychiatric and Nervous Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Psychiatric and Nervous Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Psychiatric and Nervous Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Psychiatric and Nervous Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Psychiatric and Nervous Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Psychiatric and Nervous Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Psychiatric and Nervous Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Psychiatric and Nervous Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Psychiatric and Nervous Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Psychiatric and Nervous Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric and Nervous Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Psychiatric and Nervous Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Psychiatric and Nervous Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Psychiatric and Nervous Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Psychiatric and Nervous Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Psychiatric and Nervous Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Psychiatric and Nervous Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Psychiatric and Nervous Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Psychiatric and Nervous Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Psychiatric and Nervous Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Psychiatric and Nervous Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Psychiatric and Nervous Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Psychiatric and Nervous Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Psychiatric and Nervous Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Psychiatric and Nervous Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Psychiatric and Nervous Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Psychiatric and Nervous Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Psychiatric and Nervous Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Psychiatric and Nervous Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Psychiatric and Nervous Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Psychiatric and Nervous Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Psychiatric and Nervous Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Psychiatric and Nervous Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Psychiatric and Nervous Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Psychiatric and Nervous Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Psychiatric and Nervous Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Psychiatric and Nervous Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Psychiatric and Nervous Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Psychiatric and Nervous Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Psychiatric and Nervous Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Ely Lilly Company Information
 Table 76. Ely Lilly Description and Business Overview
 Table 77. Ely Lilly Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Ely Lilly Psychiatric and Nervous Drugs Product
 Table 79. Ely Lilly Recent Developments/Updates
 Table 80. Actavis Company Information
 Table 81. Actavis Description and Business Overview
 Table 82. Actavis Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Actavis Psychiatric and Nervous Drugs Product
 Table 84. Actavis Recent Developments/Updates
 Table 85. Mylan Company Information
 Table 86. Mylan Description and Business Overview
 Table 87. Mylan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Mylan Psychiatric and Nervous Drugs Product
 Table 89. Mylan Recent Developments/Updates
 Table 90. Randox Company Information
 Table 91. Randox Description and Business Overview
 Table 92. Randox Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Randox Psychiatric and Nervous Drugs Product
 Table 94. Randox Recent Developments/Updates
 Table 95. Intellipharmaceutics Company Information
 Table 96. Intellipharmaceutics Description and Business Overview
 Table 97. Intellipharmaceutics Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Intellipharmaceutics Psychiatric and Nervous Drugs Product
 Table 99. Intellipharmaceutics Recent Developments/Updates
 Table 100. Astrazeneca Company Information
 Table 101. Astrazeneca Description and Business Overview
 Table 102. Astrazeneca Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Astrazeneca Psychiatric and Nervous Drugs Product
 Table 104. Astrazeneca Recent Developments/Updates
 Table 105. Lundbeck Company Information
 Table 106. Lundbeck Description and Business Overview
 Table 107. Lundbeck Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Lundbeck Psychiatric and Nervous Drugs Product
 Table 109. Lundbeck Recent Developments/Updates
 Table 110. Allergan Company Information
 Table 111. Allergan Description and Business Overview
 Table 112. Allergan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Allergan Psychiatric and Nervous Drugs Product
 Table 114. Allergan Recent Developments/Updates
 Table 115. GSK Company Information
 Table 116. GSK Description and Business Overview
 Table 117. GSK Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. GSK Psychiatric and Nervous Drugs Product
 Table 119. GSK Recent Developments/Updates
 Table 120. Otsuka Pharmaceutical Company Information
 Table 121. Otsuka Pharmaceutical Description and Business Overview
 Table 122. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product
 Table 124. Otsuka Pharmaceutical Recent Developments/Updates
 Table 125. Takeda Company Information
 Table 126. Takeda Description and Business Overview
 Table 127. Takeda Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Takeda Psychiatric and Nervous Drugs Product
 Table 129. Takeda Recent Developments/Updates
 Table 130. NHU Group Company Information
 Table 131. NHU Group Description and Business Overview
 Table 132. NHU Group Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. NHU Group Psychiatric and Nervous Drugs Product
 Table 134. NHU Group Recent Developments/Updates
 Table 135. Shionogi Company Information
 Table 136. Shionogi Description and Business Overview
 Table 137. Shionogi Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Shionogi Psychiatric and Nervous Drugs Product
 Table 139. Shionogi Recent Developments/Updates
 Table 140. APOTEX Company Information
 Table 141. APOTEX Description and Business Overview
 Table 142. APOTEX Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. APOTEX Psychiatric and Nervous Drugs Product
 Table 144. APOTEX Recent Developments/Updates
 Table 145. Chengdu Kanghong Pharmaceutical Company Information
 Table 146. Chengdu Kanghong Pharmaceutical Description and Business Overview
 Table 147. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product
 Table 149. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
 Table 150. HUAHAI Company Information
 Table 151. HUAHAI Description and Business Overview
 Table 152. HUAHAI Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. HUAHAI Psychiatric and Nervous Drugs Product
 Table 154. HUAHAI Recent Developments/Updates
 Table 155. Zhejiang Jianfeng Company Information
 Table 156. Zhejiang Jianfeng Description and Business Overview
 Table 157. Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Zhejiang Jianfeng Psychiatric and Nervous Drugs Product
 Table 159. Zhejiang Jianfeng Recent Developments/Updates
 Table 160. Beijing Winsunny Pharmaceutical Company Information
 Table 161. Beijing Winsunny Pharmaceutical Description and Business Overview
 Table 162. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product
 Table 164. Beijing Winsunny Pharmaceutical Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Psychiatric and Nervous Drugs Distributors List
 Table 168. Psychiatric and Nervous Drugs Customers List
 Table 169. Psychiatric and Nervous Drugs Market Trends
 Table 170. Psychiatric and Nervous Drugs Market Drivers
 Table 171. Psychiatric and Nervous Drugs Market Challenges
 Table 172. Psychiatric and Nervous Drugs Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Psychiatric and Nervous Drugs
 Figure 2. Global Psychiatric and Nervous Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Psychiatric and Nervous Drugs Market Share by Type: 2024 & 2031
 Figure 4. Antidepressants Product Picture
 Figure 5. Anti-anxiety Product Picture
 Figure 6. Antipsychotic Product Picture
 Figure 7. Mood Stabilizing Product Picture
 Figure 8. Stimulant Medications Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Psychiatric and Nervous Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Psychiatric and Nervous Drugs Market Share by Application: 2024 & 2031
 Figure 12. Hospital Pharmacies
 Figure 13. Retail Pharmacies
 Figure 14. Online Pharmacies
 Figure 15. Global Psychiatric and Nervous Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Psychiatric and Nervous Drugs Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Psychiatric and Nervous Drugs Sales (2020-2031) & (K Units)
 Figure 18. Global Psychiatric and Nervous Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 19. Psychiatric and Nervous Drugs Report Years Considered
 Figure 20. Psychiatric and Nervous Drugs Sales Share by Manufacturers in 2024
 Figure 21. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Psychiatric and Nervous Drugs Players: Market Share by Revenue in Psychiatric and Nervous Drugs in 2024
 Figure 23. Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Psychiatric and Nervous Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Psychiatric and Nervous Drugs Sales Market Share by Country (2020-2031)
 Figure 26. North America Psychiatric and Nervous Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. United States Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Psychiatric and Nervous Drugs Sales Market Share by Country (2020-2031)
 Figure 30. Europe Psychiatric and Nervous Drugs Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Psychiatric and Nervous Drugs Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Psychiatric and Nervous Drugs Revenue Market Share by Region (2020-2031)
 Figure 38. China Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. China Taiwan Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Latin America Psychiatric and Nervous Drugs Sales Market Share by Country (2020-2031)
 Figure 48. Latin America Psychiatric and Nervous Drugs Revenue Market Share by Country (2020-2031)
 Figure 49. Mexico Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Brazil Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Argentina Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Middle East and Africa Psychiatric and Nervous Drugs Sales Market Share by Country (2020-2031)
 Figure 53. Middle East and Africa Psychiatric and Nervous Drugs Revenue Market Share by Country (2020-2031)
 Figure 54. Turkey Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Saudi Arabia Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. UAE Psychiatric and Nervous Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Global Sales Market Share of Psychiatric and Nervous Drugs by Type (2020-2031)
 Figure 58. Global Revenue Market Share of Psychiatric and Nervous Drugs by Type (2020-2031)
 Figure 59. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 60. Global Sales Market Share of Psychiatric and Nervous Drugs by Application (2020-2031)
 Figure 61. Global Revenue Market Share of Psychiatric and Nervous Drugs by Application (2020-2031)
 Figure 62. Global Psychiatric and Nervous Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 63. Psychiatric and Nervous Drugs Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS